Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
Status:
Terminated
Trial end date:
2021-06-02
Target enrollment:
Participant gender:
Summary
The ongoing COVID-19 pandemic affects millions of humans worldwide and has led to thousands
of acute medical hospitalizations. There is evidence that hospitalized cases often suffer
from an important infection-related coagulopathy and from elevated risks of thrombosis.
Anticoagulants may have positive effects here, to reduce the burden of thrombotic disease and
the hyperactivity of coagulation, and may also hold beneficial anti-inflammatory effects
against sepsis and the development of ARDS.
The investigators hypothesize that high-dose anticoagulants, compared with low-dose
anticoagulants, lower the risk of venous and arterial thrombosis, disseminated intravascular
coagulation (DIC) and mortality. This open-label controlled trial will randomize hospitalized
adults with severe COVID-19 infection to therapeutic anticoagulation vs. thromboprophylaxis
during the hospital stay.